Salacia extract improves post-prandial glucose and insulin response: a randomized double-blind placebo-controlled, cross-over study in healthy volunteers

OmniActive Health Technologies Ltd (Canada)0 个研究点目标入组 40 人开始时间: 2016年2月19日最近更新: 2018年8月20日

适应症

试验速览

•1. Male and female subjects aged 18-55 years of age (both ages inclusive), of BMI 24.5 to 29.5 Kg/ m2
•2. Participants required to avoid all dietary supplements, OTC or any foods interfere with post-prandial glucose and insulin before and throughout the study period and not allowed to drink alcoholic beverages or caffeine during the period of the study
•3. Non smokers
•4. No pregnant and lactating women
•5. Signed consent form

•1. Participation in any bioavailability/bioequivalence/pharmacokinetic study or received an investigational drug within a period of 3 calendar months prior to check in of period one
•2. Use of dietary supplements to reduce body weight or metabolic health management at least 30 days before check in of period one
•3. Use of hormone replacement therapy for a period of 6 calendar months prior to check in of period one
•4. History of drug abuse, or alcohol dependence or abuse
•5. History of any allergies (asthma, urticaria) including drug allergies
•6. Known hypersensitivity or allergy to Salacia extract or any of the excipients or related drugs.
•7. Smokers, prescriptions, chronic conditions such as hypertension, diabetes , inflammatory disorders, cardiovascular disease and cancer etc

发起方

OmniActive Health Technologies Ltd (Canada)